Marinus Pharmaceuticals Inc (NASDAQ: MRNS)’s stock price has soared by 4.46 in relation to previous closing price of 1.57. Nevertheless, the company has seen a gain of 11.56% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-08 that Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago.
Is It Worth Investing in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) Right Now?
MRNS has 36-month beta value of 1.13. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRNS is 51.15M, and currently, short sellers hold a 8.83% ratio of that float. The average trading volume of MRNS on May 08, 2024 was 1.91M shares.
MRNS’s Market Performance
MRNS stock saw a decrease of 11.56% in the past week, with a monthly decline of -80.43% and a quarterly a decrease of -83.45%. The volatility ratio for the week is 8.65%, and the volatility levels for the last 30 days are 13.92% for Marinus Pharmaceuticals Inc (MRNS). The simple moving average for the past 20 days is -31.28% for MRNS’s stock, with a -78.91% simple moving average for the past 200 days.
Analysts’ Opinion of MRNS
Many brokerage firms have already submitted their reports for MRNS stocks, with Robert W. Baird repeating the rating for MRNS by listing it as a “Neutral.” The predicted price for MRNS in the upcoming period, according to Robert W. Baird is $2 based on the research report published on April 16, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see MRNS reach a price target of $3, previously predicting the price at $24. The rating they have provided for MRNS stocks is “Sector Perform” according to the report published on April 15th, 2024.
Oppenheimer gave a rating of “Perform” to MRNS, setting the target price at $9 in the report published on August 11th of the previous year.
MRNS Trading at -74.24% from the 50-Day Moving Average
After a stumble in the market that brought MRNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.44% of loss for the given period.
Volatility was left at 13.92%, however, over the last 30 days, the volatility rate increased by 8.65%, as shares sank -79.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -83.30% lower at present.
During the last 5 trading sessions, MRNS rose by +13.61%, which changed the moving average for the period of 200-days by -83.06% in comparison to the 20-day moving average, which settled at $2.0655. In addition, Marinus Pharmaceuticals Inc saw -84.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNS starting from Shafer Christina, who sale 2,153 shares at the price of $9.56 back on Feb 20 ’24. After this action, Shafer Christina now owns 60,308 shares of Marinus Pharmaceuticals Inc, valued at $20,583 using the latest closing price.
MANNING MARTHA E, the SVP, GEN. COUNSEL & CORP. SEC. of Marinus Pharmaceuticals Inc, sale 1,894 shares at $9.57 during a trade that took place back on Feb 20 ’24, which means that MANNING MARTHA E is holding 52,966 shares at $18,126 based on the most recent closing price.
Stock Fundamentals for MRNS
Current profitability levels for the company are sitting at:
- -4.24 for the present operating margin
- 0.93 for the gross margin
The net margin for Marinus Pharmaceuticals Inc stands at -4.56. The total capital return value is set at -1.01. Equity return is now at value -213.02, with -65.70 for asset returns.
Based on Marinus Pharmaceuticals Inc (MRNS), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -1.08. The debt to equity ratio resting at 6.54. The interest coverage ratio of the stock is -15.63.
Currently, EBITDA for the company is -130.93 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 2.47. The receivables turnover for the company is 8.16for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To put it simply, Marinus Pharmaceuticals Inc (MRNS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
